Brands
Kyoorius announces the fourth edition of ‘Kyoorius Design Awards 2016’
MUMBAI: The fourth Edition of the Kyoorius Design Awards, held in association with D&AD, opened for entries from Monday 27 June 2016. Kyoorius called for entries from across India for a total of 10 categories and 56 sub-categories.
The fourth edition of the Kyoorius Design Awards, brings to fore the brightest talents and best works in the field of design. Across multiple categories, the Awards cover the world of design from branding, editorial, product, and spacial design to writing for design. Not only do they celebrate design, but every year the Awards dig out undiscovered gems, new studios and designers – talent just waiting to be recognised.
The awards can be entered by any company or individual, entry is not restricted to design studios or advertising agencies. Kyoorius will promote the awards across corporate, Design Houses, Event companies, Brand Consultants etc. Kyoorius, for the first time ever, introduced the concept of Open Jury – the jury sessions are open to the industry people to watch, learn, check and benefit from the discussions and display of entries. The Jury session will be held from 2nd September to 4 September to May in Mumbai at Ecole Intuit Lab.
In coordination with D&AD, the jury will be a mix of International (West and East) and local jurors. Like every year, the awards will uphold the zero- tolerance policy for scam ads. Gabor Schreier, Executive Creative Director, Saffron Brand Consultants will head the jury.
Kyoorius founder & CEO Rajesh Kejriwal commented, “Awards are primarily to inspire and motivate the industry achievers. At Kyoorius Design Awards, the name does not matter – Merit does. We know that Designers are a terribly undervalued kind; and we are out to prove them all wrong. Because we love you more. I am also happy with the response that we have always got for having a transparent open jury process and we shall continue to do so. I personally feel that many studios/agencies have done brilliant work in the last year and hence I am expecting a lot more participation of more agencies.”
The Kyoorius Design Awards show will be held on October 1 2016 at Designyatra held this year at Fairmont Hotel, Jaipur. The awards show will be attended by well over 1250 professionals.
The Kyoorius Creative Awards are presented by ZEE TV.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
